NASDAQ:XENE Xenon Pharmaceuticals Q3 2026 Earnings Report $38.02 0.00 (0.00%) Closing price 10/2/2026 04:00 PM EasternExtended Trading$38.05 +0.03 (+0.08%) As of 10/2/2026 07:32 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast Xenon Pharmaceuticals EPS ResultsActual EPSN/AConsensus EPS -$1.17Beat/MissN/AOne Year Ago EPSN/AXenon Pharmaceuticals Revenue ResultsActual RevenueN/AExpected Revenue$1.33 millionBeat/MissN/AYoY Revenue GrowthN/AXenon Pharmaceuticals Announcement DetailsQuarterQ3 2026Date11/2/2026TimeAfter Market ClosesConference Call DateMonday, November 2, 2026Conference Call Time4:30PM ETConference Call ResourcesEarnings HistoryCompany Profile Xenon Pharmaceuticals Earnings HeadlinesXenon CFO buys 15,000 sharesOctober 4 at 4:02 AM | americanbankingnews.comXenon Pharmaceuticals (NASDAQ:XENE) Stock: Insider Ian Mortimer Purchases 30,000 SharesOctober 3 at 4:22 AM | americanbankingnews.comYour book attachedBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time through a temporary download link. He plans to charge for it soon. Download your copy now and lock it in at no cost, regardless of future pricing. | Profits Run (Ad)Xenon Pharmaceuticals (NASDAQ:XENE) Stock: Insider Thomas Patrick Kelly Buys 15,000 SharesOctober 3 at 4:22 AM | americanbankingnews.comXenon Pharmaceuticals Inc. (NASDAQ:XENE) Receives Average Rating of "Moderate Buy" from BrokeragesOctober 3 at 3:03 AM | americanbankingnews.comXenon Pharmaceuticals (NASDAQ:XENE) Shares Climb 5.2% After Insider Buying ActivityOctober 3 at 2:24 AM | americanbankingnews.comSee More Xenon Pharmaceuticals Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Xenon Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Xenon Pharmaceuticals and other key companies, straight to your email. Email Address About Xenon PharmaceuticalsXenon Pharmaceuticals (NASDAQ:XENE) is a clinical-stage biopharmaceutical company focused on developing medicines for neurological and psychiatric disorders. The company uses research in ion channels and neuronal signaling to identify potential treatments for conditions with significant unmet medical needs. Xenon’s lead investigational medicine is azetukalner, also known as XEN1101, a selective potassium channel opener being evaluated for epilepsy and major depressive disorder. The company is also advancing additional programs aimed at genetically defined epilepsies and other disorders of the central nervous system. Its medicines remain in development and are subject to clinical and regulatory review. Founded in 1996 and headquartered in Vancouver, British Columbia, Xenon conducts research and clinical development activities in North America and works with external collaborators to advance its programs. The company’s operations are supported by a leadership team with experience in biotechnology, pharmaceutical development and neuroscience, including President and Chief Executive Officer Ian Mortimer.View Xenon Pharmaceuticals ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles MarketBeat Week in Review – 09/28 - 10/02Could Nike’s Brutal Sell-Off Finally Be Running Out of Steam?Time to Nibble on MCD Stock After it Enters Oversold Territory?Liberty Energy’s AI Power Push Has Wall Street DividedMcCormick Stock Trades Cheap, Offers Dividend Growth and Unilever Deal UpsideMicron’s Earnings Reveal Why the AI Memory Boom May Last LongerAnthropic's IPO Could Put Amazon's and Alphabet's Paper Profits to the Test Upcoming Earnings PepsiCo (10/8/2026)Delta Air Lines (10/9/2026)America Movil (10/13/2026)Citigroup (10/13/2026)The Goldman Sachs Group (10/13/2026)JPMorgan Chase & Co. (10/13/2026)Wells Fargo & Company (10/13/2026)Johnson & Johnson (10/13/2026)UnitedHealth Group (10/13/2026)Bank of America (10/14/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
